Group items tagged

Pharmacy professionals to be included as key stakeholders in the implementation, delivery and evaluation of a wide range of genomic services, said the Royal Pharmaceutical Society (RPS). RPS's statement has been developed in collaboration with pharmacy organisations who have co-badged the report, such as the British Oncology Pharmacy Association, the UK Clinical Pharmacy Association, Association of Pharmacy Technicians and the College of Mental Health Pharmacy. It looks at current and future roles for pharmacy professionals in genomic medicine across many aspects of practice such as person-centred care and collaboration, professional practice, education, leadership, management and research. Pharmacists and pharmacy technicians in the UK have already established roles in the application of genomic medicine in some areas of practice, such as antimicrobial stewardship and infectious diseases, and the management of certain genetic conditions, such as cystic fibrosis. The society believes, the current role of pharmacy professionals in genomics can be expanded upon in the future to both lead and support many relevant aspects of genomic implementation. These are described across all healthcare sectors, within the Genome UK strategy produced by the UK Government, and within the implementation plans published in England, Scotland and Wales. Lead for Pharmacogenomics at RPS Sophie Harding said: "Pharmacy professionals are the gatekeepers of medication safety and efficacy across all areas of healthcare. They are skilled at interpreting complex scientific data and use evidence-based medicine to maximise the benefits of treatments for patients, whilst supporting shared decision-making with patients and the multidisciplinary team.

Patient safety should remain a top priority in any healthcare setting. People should always receive the right advice, and pharmacists aren't 'GPs on the cheap.' Staff should be fully trained, and medical equipment should be correctly maintained at all times. In turn, this helps create a safer environment for patients and professionals alike. In this article, we'll discuss some of the factors that can enhance patient safety in healthcare settings. AUTOMATION AND MONITORING Automating processes within a facility can help streamline operations. This has the potential to reduce or eliminate human error that could result in serious injury or death. In addition, automated systems often provide instant alerts when something goes wrong - allowing medical staff to react quickly and appropriately. Automated solutions can help facilities achieve hand hygiene monitoring standards, and it's possible to schedule a demo and see their outcomes. They can reduce staff sick time and HAIs, as well as Joint Commission citations and associated costs. Monitoring helps ensure compliance with safety protocols. It's essential for improving patient safety and gaining data on all aspects of a facility's operations. It also helps organizations track the effectiveness of their protocols and procedures over time. This helps them constantly evaluate and refine their policies, to maximize patient safety benefits. ADEQUATE STAFFING In order to provide quality care, it's essential to have enough staff on hand to meet patient needs and ensure all protocols are being followed. Without this, healthcare providers may struggle to provide prompt, efficient care - which can put patient safety at risk. Adequate staffing levels should be determined by a variety of factors. They include patient numbers, the complexity of care required, and the size and layout of the facility.

The Royal Pharmaceutical Society (RPS) and Pharmacist Support hosted a roundtable on the impact of pharmacy workforce wellbeing on patient safety on Wednesday (17 May). It also released its annual Workforce Wellbeing Survey which showed continued pressures on pharmacy teams. The discussion explored the actions needed to support staff so they can continue providing safe and effective patient care and included representatives from the NHS, professional bodies, employers, trade unions, education and regulators. A report of the roundtable will be published in the summer. Amandeep Doll, RPS Head of Professional Belonging, said: "We know that pharmacy teams go above and beyond for their patients, but are also under enormous pressure. "Now more than ever, we need to strive to make the pharmacy profession more inclusive and ensure that everyone's wellbeing is supported. "It is vital that we do all we can to encourage people into pharmacy and to support them so they can enhance their skills, develop their careers, and continue to deliver high-quality patient care. "This discussion was a welcome step and showed that making a difference for staff wellbeing requires a concerted effort from stakeholders across the whole of pharmacy.

Labour's Paulette Hamilton has raised concerns regarding the increasing reliance on pharmacy technicians in clinical practice due to staffing shortages within pharmacies. At the recent Pharmacy Inquiry session, Hamilton highlighted the mounting pressure on technicians to take on more responsibilities beyond their qualifications, attributing it to the launch of Pharmacy First in January. With almost 50,000 Pharmacy First consultations conducted in the first month alone as per a report by the Company Chemists' Association, Hamilton expressed apprehension about technicians being classified under the broad term of "pharmacy professionals," blurring the distinction between their roles and those of clinical pharmacists. She further drew parallels between this situation and the scrutiny faced by physician associates (PAs) in GP practices following a patient's death due to misdiagnosis and cautioned against technicians performing tasks beyond their expertise and urged policymakers to prevent similar incidents in pharmacy settings. Health Minister Dame Andrea Leadsom responded by defending the current approach, denying any "blurring of the edges" and emphasizing patient safety as the top priority.

In a bid to bolster professional leadership within the pharmacy sector, the four government Chief Pharmaceutical Officers (CPhOs) have embarked on a significant initiative, forming the UK Pharmacy Professional Leadership Advisory Board (UKPPLAB). In a recent communication, all pharmacists and pharmacy technicians received confirmation of the board members selected by the CPhOs, alongside a note from the board's appointed chair, who was chosen collectively by the four CPhOs and reports directly to the CPhO for England. Over three years, the 21-member Board will implement recommendations from the UK Commission on Pharmacy Professional Leadership's report aimed to enhance professional fulfillment among pharmacists while simultaneously augmenting patient safety standards. This announcement also follows with the appointment of Sir Hugh Taylor as its Independent Chair and the appointment of Independent Expert Members who expressed his delight over the role's "potential to lead and support collaboration across the professions in the UK". However, the move has been met with cautious optimism from the Pharmacists' Defence Association (PDA), urging the new board to uphold transparency and openness to garner trust among pharmacists.

Gisela Abbam today (March 14) officially succeeded Nigel Clarke as new chair of the General Pharmaceutical Council (GPhC). She was appointed in mid-Feruary. The council paid tribute to its outgoing chair for his major contribution to pharmacy regulation and his focus on patient safety for the past eight years on the role. During his tenure Clarke has overseen significant changes to how the GPhC regulates pharmacists, pharmacy technicians and pharmacies to help drive improvements in professional practice and protect patient safety. Chief executive of the GPhC, Duncan Rudkin, said: "I would like to pay tribute to Nigel for everything he has done to support continuous improvement and assure the quality and safety of pharmacy for the benefit of patients and the public.

Professor Harry McQuillan has said community pharmacists in the UK must change their focus from an 'accuracy of supply' to a 'safety of supply' model when it comes to dealing with patients. "The main take away message from tonight's lecture is for pharmacy professionals to really challenge themselves about whether they are focused on accuracy of supply or safety of supply," he said at this year's UCL School of Pharmacy Lecture in London on Thursday, 15 June. "For our community pharmacists it must be about safety, including prescribing, and ensuring patients and citizens get the maximum benefit from prescribed medicines. "To deliver this, we need to invest in our teams - harness technology and always be willing to take the next step in a more clinical future." The Chief Executive Office of Community Pharmacy Scotland, however, noted that at a time when the UK was grappling with an unprecedented national debt crisis exacerbated by severe cost of living and spiraling inflation, community pharmacy will need to make a "compelling case" of where the priority should be in the sector. Expanding on the financial woes of the country, he compared the current national debt of the UK, which stood at a staggering 270 percent of GDP in September 2022, with the previous record-breaking national debt of 250 per cent at the end of WWII.

A judicial review claim launched by the British Medical Association (BMA) against the General Medical Council (GMC) has parallelly intensified Pharmacists' Defence Association's (PDA) scrutiny over the use of the term 'pharmacy professionals'. PDA has criticised the evolving definition of 'pharmacy professionals,' and the potential risks to patient safety amidst regulatory ambiguity as part of "a far wider agenda." Concerns stem from what the PDA perceives as a blurring of distinctions between pharmacists and pharmacy technicians as "attempted homogenisation" by bodies like the General Pharmaceutical Council (GPhC), NHS, and Royal Pharmaceutical Society (RPS). Raising similar issue as the BMA against the GMC over its use of 'medical professionals for doctors and Medical Associate Professions (MAPs), Mark Koizol, Chairman of the PDA has said:

The professional leadership body for pharmacists has urged the General Pharmaceutical Council's (GPhC) to make it mandatory to have a chief pharmacist within organisations to ensure transparency for patients, the public and pharmacy staff. On 23 January, the GPhC launched a consultation seeking views on the new draft Standards for Chief Pharmacists it has developed to strengthen pharmacy governance. These standards outlined the professional responsibilities and qualifications required by a chief pharmacist to support their organisation and its staff to deliver "safe and effective" pharmacy services. The pharmacy regulator highlighted the importance of having a registered chief pharmacist meeting these standards in hospitals (or relevant settings) to benefit from the new legislation regarding accidental errors. In response to the consultation, the RPS expressed that while meeting these standards could enhance pharmacy governance, they may not provide the framework needed to fully support staff in reporting and learning from errors.

Medicines and Healthcare products Regulatory Agency (MHRA) has urged the healthcare professionals to share their views on the consultation on 'how MHRA communicate with healthcare professionals to improve medicines and medical devices' safety'. Through this consultation the agency wants to review its approach to engagement with healthcare professionals to improve the safety of medicines and medical devices. "We want to ensure that healthcare professionals are receiving actionable information and guidance on safe use of medicines and medical devices that they can take into their working practice, providing timely advice to patients," said MHRA. "We need to improve the way we communicate with healthcare professionals. We want to hear from you to enable us to transform how we communicate with you and how we work together on our common goal of greater patient safety."

The General Pharmaceutical Council (GPhC) recently issued a public apology after they mistakenly referred to pharmacy technicians as 'pharmacist technicians' in a council paper. It has also written a letter of apology to the President of the Association of Pharmacy Technicians (APTUK) for the error they made. Meanwhile, the Pharmacists' Defence Association (PDA) has raised concern about an equally worrying trend in which pharmacists are being referred to by the GPhC and others as 'pharmacy professionals', a term that is also used for pharmacy technicians. The association said this creates confusion in the minds of the public about the two roles and responsibilities, which are very different, as well as have impact upon the workplace.

Following concerns raised about cracked cartridges and insulin leaks, the Medicines and Healthcare products Regulatory Agency (MHRA) has issued a national patient safety alert for the NovoRapid PumpCart prefilled insulin cartridge and the Roche Accu-Chek Insight Insulin pump system. The regulator have asked patients to check the pre-filled glass insulin cartridge for cracks before use. It advised against using the cartridge if it has been dropped even if no cracks are visible and urged to closely follow the updated handling instructions in the pump user manual when changing pre-filled glass insulin cartridges. In some of the reported leakage incidents, the cartridges were found to be cracked and provided an inadequate supply of insulin to patients. Leakages also occurred in cases where no cracks in the cartridge were visible, the regulator said. In some patients there were consequences of not receiving enough insulin from their pump system, including reports of severely high blood sugar and diabetic ketoacidosis, a serious complication of diabetes when the body produces high levels of blood acids called ketones. Healthcare professionals are being advised to contact patients over the next six months using said device to discuss their individual needs and source an alternative pump where appropriate. "Because of the rare risk of insulin leakage from the Roche Accu-Chek Insight Insulin Pump, patients should check the pre-filled glass insulin cartridge for any cracks prior to usage," Dr June Raine, MHRA chief executive, said.

The General Pharmaceutical Council (GPhC) has raised concerns over the rising risks related to online pharmacy services. It revealed over 30 per cent of its open Fitness to Practise (FtP) cases were related to online pharmacy, which is disproportionate to the sector of the market that online services occupy. The regulator has advised pharmacists and pharmacy owners providing online services that they should "not work with online providers who try to circumvent the regulatory oversight put in place within the UK to ensure patient safety". In the past five months, the Council has imposed seven interim orders on the registration of pharmacists who have worked for or with online prescribing services - after identifying serious concerns with their practice. It said: "These pharmacists were working as pharmacist independent prescribers for online services or were dispensing medicines prescribed online. Some of these pharmacists were the Responsible Pharmacist (RP) or the Superintendent Pharmacist (SP)."

The Department of Health and Social Care (DHSC), led by Victoria Atkins MP and Maria Caulfield MP, has unveiled proposed updates to the NHS Constitution for England, aiming to fortify the principles of privacy, dignity, and safety for all patients. Martha's rule was prompted by a campaign led by the parents of 13-year-old Martha Mills who tragically succumbed to sepsis after staff at King's College Hospital failed to escalate her care to intensive care, despite her family's pleas regarding her worsening condition in 2021. Under the new guidance is the introduction of Martha's Rule, empowering patients to request intimate care from someone of the same biological sex ensuring that the distinct needs of men and women are recognized and addressed. Patients and their loved ones can exercise the right to "access to a rapid review from outside the care team if the patient is deteriorating." The consultation on the proposed updates is set to run for eight weeks, inviting feedback from patients, healthcare professionals, and stakeholders for a review

Three batches of Mexiletine hydrochloride 50mg, 100mg and 200 mg hard capsules manufactured by Clinigen Healthcare has been recalled. Pharmacists are urged to quarantine the said batches and return it to the supplier by or before 12 August. Clinigen Healthcare Ltd has initiated a recall of three batches of Mexiletine hydrochloride hard capsules due to a potential risk of under dose or overdose, which could have consequences for the safety of patients. The manufacturer has confirmed that no alternative batches of Mexiletine hydrochloride 50mg, 100mg or 200mg hard capsules will be available until later in the year, therefore the recall of these batches from patients should only be considered where patients have access to appropriate alternative products. See below for more information on resupplying patients with alternative products. "Patients should be advised not to stop any treatments without consulting their relevant healthcare professional. The risks of suddenly stopping medication for ventricular arrhythmias is higher than the potential risk presented by too much or too little of the active ingredient in the capsule."

Pharmaceutical recalls are complicated and expensive, just like in any other business. Pharmaceutical recalls, however, pose a further risk because they might change both short- and long-term health effects. To ensure smooth recalls with few negative effects on public health, it is crucial to understand the pharmaceutical product recall procedure and the roles of each key player. Throughout the recall procedure, patient safety is crucially ensured by the FDA, pharmaceutical companies, pharmacy technicians, and other healthcare professionals. Learning about pharma recalls, procedures, and responsibilities is essential for guaranteeing patient safety for key actors like the Food and Drug Administration (FDA), manufacturers, and other medical specialists. RECALL CLASSIFICATIONS Recalls can fall into one of three categories-class I, II, or III-with class I being the most serious and lethal. Products that have the potential to result in serious, permanent complications or death are subject to Class I recalls. Class II recalls are recommended for product flaws that have a low likelihood of harmful events or that can result in reversible side effects. Last but not least, class III recalls typically arise from problems with packaging that do not pose a risk. Since they are frequently issued out of an abundance of prudence rather than due to any negative impacts, many people may even describe this kind of recall as benign.

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a consultation on the reclassification of codeine linctus to a prescription-only medicine after considering multiple Yellow Card reports for its opioid effects, rather than for its intended use as a cough suppressant. This medication is currently licensed as a pharmacy medicine, which means that it is available to purchase over the counter in pharmacies. If reclassified as a prescription-only medicine, all strengths of codeine linctus will only be available upon presentation of a prescription. Dr Alison Cave, MHRA Chief Safety Officer, said: "Codeine linctus is an effective medicine, but as it is an opioid, its misuse and abuse can have major health consequences. Every response received will help us to develop a broader view on whether codeine linctus should be restricted to prescription-only status. We want to hear from members of the public, health professionals and others who would be affected by this potential change so we can make a properly considered decision for the benefit of patients, carers, and healthcare professionals across the UK.

"Our main concerns are that the use of what they call an asynchronous supply, where the prescriber neither sees nor talks to the patient at the time they issue the prescription, does lay itself open to perhaps people getting hold of medication that they shouldn't," the Head of Policy, PDA said. The Pharmacists' Defence Association (PDA) engages in a critical conversation on BBC Radio 4's Woman's Hour, shedding light on the online prescribing of weight loss drugs and advocating for safer practices. The PDA's spokesperson, Head of Policy Alima Batchelor, emphasised the importance of adhering to professional guidelines to ensure patient safety and mitigate regulatory concerns. During the feature, the PDA highlighted the complexities and risks associated with online supply chains, stressing the necessity for direct clinical consultations and pharmacist involvement in medication management. ""There are guidelines and advice about verification within the DiCE guidance, but it doesn't go quite far enough for us. We are concerned when patients decline to allow the online prescriber to advise their GP of what they're taking," Batchelor highlighted.

Royal Pharmaceutical Society (RPS) and the Royal College of General Practitioners in Scotland hosted an event celebrating the collaborative work of the health professions and policy makers in Scotland on reducing the environmental harm from prescribing and medicines use. To share priorities for the Scottish Government, Alpana Mair, Head of Effective Therapeutics and Prescribing spoke and National Clinical Director Jason Leitch appeared virtually. Gillian MacKay MSP, Scottish Greens spokesperson for Health and Social Care also joined in-person. Medicines account for around 25% of the NHS's carbon emissions and have an ecological impact when they enter our wastewater system or our rivers and oceans. Tackling the impact of prescribing will be a key part of meeting the ambition of a net zero NHS Scotland by 2040 at the latest. Together, RCGP Scotland and RPS have held two roundtable events on sustainable prescribing, and in June 2022, released a joint statement calling for a wide range of actions, which was signed by the Academy of Medical Royal Colleges and Faculties in Scotland, the Royal College of Physicians of Edinburgh, the Royal College of Anaesthetists, the College of Radiographers, Royal College of Nursing, Queen's Nursing Institute Scotland and Chartered Society of Physiotherapy. Continuing the work of RPS at the International Forum on Quality and Safety in Healthcare, the event aims to mark an opportunity for health professionals and decision makers alike to join a global movement of sustainability in healthcare, and pledge to continue the important work of cutting the climate impact of medicine use while maintaining the highest level of patient care and safety.

The Medicines and Healthcare products Regulatory Agency (MHRA) has reminded healthcare professionals prescribing aripiprazole to alert patients about its possible side effects, following a rise in the number of reports of gambling disorder associated with the drug. Patients taking aripiprazole, which is used for the treatment of schizophrenia and bipolar disorder, are at risk of developing unusual urges or cravings that they cannot resist, including behaviours such as addictive gambling, excessive eating or spending, or an abnormally high sex drive. The regulator has received 69 reports of gambling or gambling disorder suspected to be caused by aripiprazole in the last 14 years via the Yellow Card Scheme, out of which 32 were received between 1 January and 31 August this year. Alison Cave, MHRA Chief Safety Officer, said: "The number of reports for suspected gambling and other impulsive behaviours associated with aripiprazole are small in comparison to the frequency with which it is prescribed, but the consequences for any patient developing these conditions can be significant."